Investigation Report on Chinese Recombinant Human Erythropoietin(rhEPO) Market, 2020-2024

$2,600$3,900

Clear

Description

Description
There are approximately 400,000 to one million people with hemophilia in the world. Among them, there are about 100,000 to 200,000 patients in China. The registered hemophilia patients in China are less than 20,000, because most patients give up treatment due to the expensive medical expenses. Those who lack coagulation factor VIII account for 80% to 85% of the hemophilia A patients. Currently, there is no cure for hemophilia, treatment for which on the market are all alternatives. Coagulation factors are the main drugs.
In 1992, Baxter (Baxalta) publicized the first recombinant factor VIII(rFVIII). Because it has the same effects as natural coagulation factors without risks of blood-borne virus contamination, it is very popular in the market. The developed countries master mature technologies of recombinant coagulation factors. For example, recombinant coagulation factor VIII now has experienced four rounds of upgradation. The main manufacturers are Bayer, Baxalta, Pfizer, etc. By the end of 2020, no domestic recombinant coagulation factor VIII has been launched in China.
According to CRI’s market research, Recombinant Factor Ⅷ developed rapidly after entering China. Its annual sales increased from less than CNY 6 million in 2009 to CNY481 million in 2019, and the CAGR reached 55% in 2009 to 2019. Currently, Recombinant Factor Ⅷ sold on the Chinese market is all imported from Bayer, Baxalta and Pfizer. According to sales value, Bayer accounted for nearly 70% of the Chinese market in 2019.
CRI forecasts that with the development of China’s economy, patients with hemophilia are more able to pay medical expenses. It is expected that the market scale of Recombinant Factor Ⅷ in China will continue to increase from 2020 to 2024. After 2022, there is possibility that Chinese companies may launch Recombinant Factor Ⅷ.

Topics Covered:
-Development of Recombinant Factor Ⅷ in China
-Sales volume and value of Recombinant Factor Ⅷ in China
-Sales volume and value of Recombinant Factor Ⅷ in regions of China
-Price of Recombinant Factor Ⅷ in the Chinese market
-Key players of Recombinant Factor Ⅷ in the Chinese market
-Research progress of Chinese companies on Recombinant Factor Ⅷ
-Chinese market prospects on Recombinant Factor Ⅷ from 2020 to 2024

Table of Contents

Table of Contents
1 Relevant Concepts of Recombinant Factor Ⅷ
1.1 Indication
1.2 Development in China
1.3 Patents and Government Approval on Drugs

2 Sales of Recombinant Factor Ⅷ in China, 2015-2019
2.1 Sales Value of Recombinant Factor Ⅷ in China
2.1.1 Overall Sales Value of Recombinant Factor Ⅷ in China
2.1.2 Sales Value of Recombinant Factor Ⅷ by regions of China
2.2 Sales Volume
2.2.1 Overall Sales Volume of Recombinant Factor Ⅷ in China
2.2.2 Sales Volume of Recombinant Factor Ⅷ by regions of China
2.3 Sales of Recombinant Factor Ⅷ by Dosage Forms in China

3 Major Manufacturers of Recombinant Factor Ⅷ in China, 2015-2019
3.1 Market Share of Recombinant Factor Ⅷ in China by Major Manufacturers
3.1.1 Market Share of Recombinant Factor Ⅷ Manufacturers in China by Sales Value
3.1.2 Market Share of Recombinant Factor Ⅷ Manufacturers in China by Sales Volume
3.2 Bayer
3.2.1 Enterprise Profile
3.2.2 Sales of Bayer’s Recombinant Factor Ⅷ in China
3.3 Baxalta
3.3.1 Enterprise Profile
3.3.2 Sales of Baxalta’s Recombinant Factor Ⅷ in China
3.4 Pfizer
3.4.1 Enterprise Profile
3.4.2 Sales of Pfizer’s Recombinant Factor Ⅷ in China

4 Prices of Recombinant Factor Ⅷ in China, 2015-2020
4.1 Average Prices of Recombinant Factor Ⅷ in China
4.1.1 Average Prices of Recombinant Factor Ⅷ Capsules in China 2015-2019
4.1.2 Average Prices of Recombinant Factor Ⅷ Tablets in China 2015-2019
4.2 Average Prices of Bayer’ Recombinant Factor Ⅷ (Kovaltry)
4.3 Average Prices of Baxalta’s Recombinant Factor Ⅷ (Adynovate)
4.4 Average Prices of Pfizer’s Recombinant Factor Ⅷ (Xyntha)

5 Market Prospects of Recombinant Factor Ⅷ, 2020-2024
5.1 Forecast on Factors Influencing Development
5.2 Forecast on Market Size
5.3 Forecast on Development Trend

Table of Selected Charts
Chart Patents of Recombinant Factor Ⅷ in China
Chart Sales of Recombinant Factor Ⅷ in China 2015-2019
Chart Sales Value of Recombinant Factor Ⅷ in China, 2015-2019
Chart Sales Value of Recombinant Factor Ⅷ in Parts of China, 2015-2019
Chart Sales Volume of Recombinant Factor Ⅷ in China, 2015-2019
Chart Sales Volume of Recombinant Factor Ⅷ in Parts of China, 2015-2019
Chart Sales Value and Market Share of Bayer’s Recombinant Factor Ⅷ in China, 2015-2019
Chart Sales Value and Market Share of Baxalta’s Recombinant Factor Ⅷ in China, 2015-2019
Chart Sales Value and Market Share of Wyeth’s Recombinant Factor Ⅷ in China, 2015-2019
Chart Sale Price of Bayer’s Recombinant Factor Ⅷ in Some Chinese Cities, 2019-2020
Chart Sale Price of Baxalta’s Recombinant Factor Ⅷ in Some Chinese Cities, 2019-2020
Chart Forecast on Sale Price of Recombinant Factor Ⅷ in China, 2020-2024

Additional information

Publisher

Date Published

Pages

Charts

Format